All In Biotech

Drug Trial Radar · NCT06892548

A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

A Phase Ib/II, Multi-site, Open-label, Two-part Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Recommended Combination Dose of BNT324 With BNT327 in Participants With Advanced Lung Cancer

Last checked: Nov 19, 2026Latest source record: Aug 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 594 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

594

Planned (sponsor's estimate)

Start

May 2, 2025

Primary completion

Sep 2028

Study completion May 2032

Sponsor

Lead sponsor
BioNTech SEIndustry
Sponsor type
Industry
Collaborators
DualityBio Inc.
First posted
Mar 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to investigate the combination of BNT324, a B7-H3 antibody-drug conjugate (ADC) with BNT327, a programmed death-ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF) bispecific antibody, in participants with advanced/metastatic or relapsed/progressive small cell lung cancer (SCLC) and non small cell lung cancer (NSCLC).

Conditions

  • Advanced Lung Cancer

Interventions

  • BNT324Biological

    Intravenous infusion

  • BNT327Biological

    Intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1 - Occurrence of dose limiting toxicities (DLTs) by dose levelTime frame: During the DLT evaluation period, i.e., the time of initiation of the first dose of investigational medicinal product (IMP) up to 21 days]
  2. Part 1 - Occurrence of Treatment-emergent adverse events (TEAEs), serious TEAEs, treatment-related TEAEs, and treatment-related serious TEAEs by dose levelTime frame: From the time of the first dose of IMP to 90 days after the last IMP dose or until new anticancer therapy is started, whichever occurs first
  3. Part 1 - Occurrence of dose interruption, reduction, and treatment discontinuations due to TEAEs by dose levelTime frame: From the time of the first dose of IMP to 90 days after the last dose of IMP or until new anticancer therapy is started, whichever occurs first
  4. Part 2 cohorts 1 and 2 - Occurrence of TEAEs, serious TEAEs, treatment-related TEAEs, and treatment-related serious TEAEs by cohort and treatment armTime frame: From the time of the first dose of IMP to 90 days after the last IMP dose or until new anticancer therapy is started, whichever occurs first
  5. Part 2 cohorts 1 and 2 - Occurrence of dose interruption, reduction, and treatment discontinuation due to TEAEs by cohort and treatment armTime frame: From the time of the first dose of IMP to 90 days after the last IMP dose or until new anticancer therapy is started, whichever occurs first
  6. Part 2 cohorts 1 and 2 - Objective response rate (ORR) by cohort and treatment armTime frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 87 months
  7. Part 2 cohorts 3-7 - ORR by cohortTime frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 87 months

Locations

91 sites in 10 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Arizona

    Phoenix, Arizona · Recruiting

  • Precision NextGen Oncology and Research Center

    Beverly Hills, California · Recruiting

  • Cedars Sinai Medical Center

    Los Angeles, California · Recruiting

  • UCLA - David Geffen School of Medicine

    Santa Monica, California · Recruiting

  • University of Colorado Cancer Center

    Aurora, Colorado · Recruiting

  • Mayo Clinic in Florida

    Jacksonville, Florida · Recruiting

  • University of Iowa Hospitals & Clinics PARENT

    Iowa City, Iowa · Recruiting

  • Mayo Clinic-Rochester

    Rochester, Minnesota · Recruiting

  • Regional Cancer Care Associates

    Belleville, New Jersey · Recruiting

  • John Theurer Cancer Center at Hackensack UMC

    Hackensack, New Jersey · Recruiting

  • Memorial Sloan Kettering Cancer Center (MSKCC)

    New York, New York · Recruiting

  • Icahn School of Medicine at Mount Sinai PRIME

    New York, New York · Recruiting

  • Cleveland Clinic Taussig Cancer Institute Case Comprehensive Cancer Center

    Cleveland, Ohio · Recruiting

  • Texas Oncology - DFW

    Dallas, Texas · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Texas Oncology - Northeast

    Tyler, Texas · Recruiting

  • Virginia Cancer Specialists

    Fairfax, Virginia · Recruiting

  • Chris O'Brien Lifehouse

    Camperdown, New South Wales, Australia · Recruiting

  • Flinders Medical Centre

    Bedford Park, South Australia, Australia · Recruiting

  • Bendigo Hospital

    Bendigo, Victoria, Australia · Recruiting

  • Barwon Health

    Geelong, Victoria, Australia · Recruiting

  • Sunshine Hospital

    Saint Albans, Victoria, Australia · Recruiting

  • St John of God Subiaco Hospital

    Subiaco, Western Australia, Australia · Recruiting

  • The First Affiliated Hospital of Xiamen University

    Fujian, China · Recruiting

  • Affiliated Cancer Hospital and Institute of Guangzhou Medical University

    Guandong, China · Recruiting

  • Xuzhou Central Hospital

    Xuzhou, China · Recruiting

  • Anhui Provincial Cancer Hospital

    Hefei, Anhui, China · Recruiting

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Beijing GoBroad Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China · Recruiting

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China · Recruiting

  • Guangxi Medical University Cancer Hospital

    Nanning, Guangxi Zhuang, China · Recruiting

  • The First Affiliated Hospital of Xinxiang Medical University

    Weihui, Henan, China · Recruiting

  • Henan Provincial Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • Jingzhou First People's Hospital

    Jingzhou, Hubei, China · Recruiting

  • Xiangyang Central Hospital

    Xiangyang, Hubei, China · Recruiting

  • Yichang Central People's Hospital

    Yichang, Hubei, China · Recruiting

  • Hunan Province People's Hospital

    Changsha, Hunan, China · Recruiting

  • Nanjing Chest Hospital

    Nanjing, Jiangsu, China · Recruiting

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China · Recruiting

Showing 40 of 91 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.